Xenetic Biosciences (XBIO) Return on Sales (2011 - 2026)

Xenetic Biosciences (XBIO) has 15 years of Return on Sales data on file, last reported at 0.5% in Q1 2026.

• Quarterly Return on Sales rose 21.0% year-over-year to 0.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.39% (up 10.0% YoY) and the FY2025 annual result came in at 0.14%, up 4.0% from the prior year.
• Return on Sales retreated to 0.5% in Q1 2026, from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q4 2025 to a low of 0.86% in Q1 2022.
• A 5-year average of 0.52% and a median of 0.65% in 2023 frame the typical range for Return on Sales.
• The widest YoY moves for Return on Sales: up 78 bps in 2022, down 77 bps in 2022.
• Tracing XBIO's Return on Sales over 5 years: stood at 0.03% in 2022, then surged by 43 bps to 0.02% in 2023, then gained by 9 bps to 0.02% in 2024, then jumped by 52 bps to 0.01% in 2025, then plunged by 6051 bps to 0.5% in 2026.
• The last three Return on Sales figures came in at 0.5% (Q1 2026), 0.01% (Q4 2025), and 0.41% (Q3 2025), per Business Quant data.